Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 18;12(11):2860.
doi: 10.3390/diagnostics12112860.

Lectin Analysis of SARS-CoV-2-Positive Nasopharyngeal Samples Using GLYcoPROFILE® Technology Platform

Mateja Seničar  1 , Benoît Roubinet  1 , Richard Daniellou  2 , Thierry Prazuck  3 , Ludovic Landemarre  1
Affiliations

Lectin Analysis of SARS-CoV-2-Positive Nasopharyngeal Samples Using GLYcoPROFILE® Technology Platform

Mateja Seničar et al. Diagnostics (Basel). .

Abstract

Nasopharyngeal samples are currently accepted as the standard diagnostic samples for nucleic acid amplification testing and antigenic testing for the SARS-CoV-2 virus. In addition to the diagnostic capacity of SARS-CoV-2-positive crude nasopharyngeal samples, their qualitative potential for direct glycan-specific analysis, in order to uncover unique glycol profiles, was assessed. In this study we provide glycan characterization of SARS-CoV-2-positive and -negative nasopharyngeal samples directly from lectin interactions. Although with limited throughput, this study evaluated the clinical sensitivity and specificity of the GLYcoPROFILE® technology platformon45crude nasopharyngeal samples collected between November 2020 and April 2022. Each GLYcoPROFILE® of 39 SARS-CoV-2-positive samples was compared toglycoprofiling on a panel of 10 selected lectins and the results were paralleled with SARS-CoV-2-negative samples’ results. The GLYcoPROFILE® showed a clear distinction between positive and negative samples with WFA, GSL-II, PHA-L (GlcNAc-specific) and BPA (GalNAc-specific) highlighted as relevant lectins in SARS-CoV-2-positive samples. In addition, a significant, positive statistical correlation was found for these lectins (p < 0.01).

Keywords: COVID-19; GLYcoPROFILE® technology; SARS-CoV-2; lectins; nasopharyngeal samples.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of GLYcoPROFILE® technology. Recognition of SARS-CoV-2 glycan motifs by specific lectins immobilized on the microtiter plate.
Figure 2
Figure 2
GLYcoPROFILE® raw data of 4 SARS-CoV-2-positive nasopharyngeal samples on a panel of 20 lectins. Non-diluted samples were screened against selected lectins, previously adsorbed on LEctPROFILE® plate, and revealed with anti-SARS-CoV-2 antibodies (1/100).
Figure 3
Figure 3
GLYcoPROFILE® raw data of SARS-CoV-2-positive (N°1–39 in black) and -negative (N°40–45 in grey) nasopharyngeal samples on a panel of 10 lectins. Non-diluted samples were screened against selected lectins, previously adsorbed on LEctPROFILE® plate, and revealed with anti-SARS-CoV-2 antibodies (1/100).
Figure 4
Figure 4
Average of GLYcoPROFILE® fluorescence intensities interactions of nasopharyngeal SARS-CoV-2-positive and -negative samples with lectins.
Figure 5
Figure 5
GLYcoPROFILE® Heat Map representation of the fluorescence intensities of raw data of individual SARS-CoV-2-positive (from N°1 to 39) and -negative samples (from N°40 to 45). (A) GLYcoPROFILE® Heat Map with indicated viral charges (red arrow: high viral load, blue arrow: moderate viral load, no arrow: viral load not determined); (B) Regrouped GLYcoPROFILE® Heat Map according to increasing (moderate to high) viral charge. Interpretation of viral charge results for N gene amplification of SARS-CoV-2 virus according to FMS: high < 25, moderate 25–30, low > 30.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Atzrodt C.L., Maknojia I., McCarthy R.D.P., Oldfield T.M., Po J., Ta K.T.L., Stepp H.E., Clements T.P. A Guide to COVID-19: A global pandemic caused by the novel coronavirus SARS-CoV-2. FEBS J. 2020;287:3633–3650. doi: 10.1111/febs.15375. - DOI - PMC - PubMed
    1. Hamre D., Procknow J.J. A new virus isolated from the human respiratory tract. Proc. Soc. Exp. Biol. Med. 1966;121:190–193. doi: 10.3181/00379727-121-30734. - DOI - PubMed
    1. Wevers B.A., van der Hoek L. Recently discovered human coronaviruses. Clin. Lab. Med. 2009;29:715–724. doi: 10.1016/j.cll.2009.07.007. - DOI - PMC - PubMed
    1. Pyrc K., Berkhout B., van der Hoek L. Identification of new human coronaviruses. Expert. Rev. Anti. Infect. Ther. 2007;5:245–253. doi: 10.1586/14787210.5.2.245. - DOI - PubMed
    1. Tang D., Comish P., Kang R. The hallmarks of COVID-19 disease. PLoS Pathog. 2002;16:e1008536. doi: 10.1371/journal.ppat.1008536. - DOI - PMC - PubMed

LinkOut - more resources